Holen Sie sich die Stockscreener-App
15.29
2.62%
0.39
Handel nachbörslich:
15.54
0.25
+1.64%
Schlusskurs vom Vortag:
$14.90
Offen:
$15.04
24-Stunden-Volumen:
536.94K
Relative Volume:
0.89
Marktkapitalisierung:
$780.84M
Einnahmen:
$107.46M
Nettoeinkommen (Verlust:
$105.90M
KGV:
7.5409
EPS:
2.0276
Netto-Cashflow:
$243.48M
1W Leistung:
+10.56%
1M Leistung:
-19.78%
6M Leistung:
+10.88%
1J Leistung:
+64.23%
1-Tages-Spanne:
$14.95
$15.36
1-Wochen-Bereich:
$13.40
$15.36
52-Wochen-Spanne:
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
15.29 | 760.92M | 107.46M | 105.90M | 243.48M | 2.0276 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan
Theravance drops rare disease drug after late-stage trial setback - MSN
Theravance's Q4 earnings and revenues miss estimates - MSN
Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus
TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada
Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - TradingView
Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan
Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN
(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat
Theravance's Q4 Earnings and Revenues Miss Estimates - Yahoo Finance
BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
TBPH: BTIG Reiterates Buy Rating with Unchanged Price Target | T - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS - MarketBeat
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base - simplywall.st
Theravance Biopharma stock rating reiterated at Buy by BTIG on revenue beat - Investing.com Canada
Theravance Biopharma earnings beat by $0.15, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma Q4 operating income USD 20.012 million - marketscreener.com
Theravance Biopharma 2025 Earnings: Q4 Profit $61M, Revenue Misses EstimatesNews and Statistics - IndexBox
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Theravance Biopharma (TBPH) Achieves Record Quarter Amidst Strat - GuruFocus
BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million - TradingView
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Ireland's Theravance Biopharma Q4 revenue misses expectations - TradingView
Theravance Biopharma reports Q4 2025 net income $61.0M; Q4 revenue $45.9M, cash ~ $400M expected Q1 2026 - TradingView
Theravance Bio: Q4 Earnings Snapshot - kare11.com
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire
Theravance Biopharma SVP Farnum sells $433k in shares By Investing.com - Investing.com India
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH) - GuruFocus
Theravance Biopharma SVP Farnum sells $433k in shares - Investing.com
Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares - MarketBeat
Theravance Biopharma (NASDAQ: TBPH) SVP sells 31,067 shares, keeps stake - Stock Titan
Theravance Biopharma (TBPH) price target increased by 28.23% to 27.25 - MSN
Aug Retail: Why is Theravance Biopharma Inc stock going downGlobal Markets & High Win Rate Trade Tips - baoquankhu1.vn
[144] Theravance Biopharma, Inc. SEC Filing - Stock Titan
Theravance Biopharma to restructure after late-stage ampreloxetine setback - MSN
WINTON GROUP Ltd Takes $1.12 Million Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Aug Fed Impact: Can Theravance Biopharma Inc sustain its profitabilityQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50 - The Business Journals
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates - PR Newswire
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash - Yahoo Finance
Responsive Playbooks and the TBPH Inflection - Stock Traders Daily
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations - TMX Newsfile
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Portfolio Recap: Is Theravance Biopharma Inc stock showing strong momentum2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
HC Wainwright Issues Optimistic Forecast for TBPH Earnings - MarketBeat
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):